// Account brief

GSK

Life Sciences Radar, October 2026 edition. Evidence published up to 5 October 2026; job sites read on 6 October 2026. This brief covers AI in drug discovery, and research labs and data. Every link opens the public source.

Disclosure: Andrew Wyatt, Ortent's principal, was Chief Growth Officer at Sapio Sciences, a lab software company, until April 2026. He has no current relationship with, or financial interest in, Sapio or any other supplier. Software vendors, including Sapio and its competitors, appear in this brief only where public sources name them.

Status: Ortent has reviewed this brief; it has not been independently validated. It sets out what the company and others have published. Search coverage varies by company and is described under Coverage limits, and a count of zero means none was identified, not that nothing happened. It does not predict buying intent or measure operational maturity. For this radar, process and CMC development are grouped with manufacturing and excluded from research labs and data.

Scores

Theme Priority (1 to 10) Delivery (0 to 10) Stage Commitments made public, last 12 months R&D roles open on 6 Oct 2026
AI in drug discovery 6 4 live 3 2
Research labs and data 5 4 live 0 3

The scores rest only on what the company itself has published about each theme. Commitments and open roles are observed activity: they show what is being started or staffed now, and they never change a score.

Summary

GSK scores 6 out of 10 for priority and 4 out of 10 for delivery in AI in drug discovery. Its annual reports describe AI and automation platforms running now in small-molecule chemistry and oligonucleotides (Oligopolis), plus data-driven disease models in COPD, with no adoption metric published. Research labs and data scores 5 for priority and 4 for delivery, based on computational protein modelling joined to an automated lab-in-the-loop platform and AI/ML-powered automated lab systems in HIV and immunology. In the last 12 months three AI discovery commitments were made public, against two the year before: an expanded Relation Therapeutics collaboration (announced by Relation only), a Noetik foundation model licence and a single-cell collaboration with the Teichmann Laboratory. No research labs and data commitment was made public in either year, but on 6 October 2026 GSK had 3 research labs and data roles open, including a Lab Robotics Manager and a Lab Data Manager supporting MyLabData, and 2 AI in drug discovery roles in modelling.

AI in drug discovery

What the company says: Priority 6

At every step of the R&D process, we are using data tech, including AI, and platform technologies to be faster, more effective and more predictive in discovering and developing innovative medicines and vaccines.

GSK Annual Report 2025, 5 Mar 2026, p. 5

Our AI-powered, end-to-end oligonucleotide platform, 'Oligopolis', which incorporates the Elsie platform we acquired in 2024, is redefining research in chemistry and biology. The platform automates cycles of design, synthesis and testing

GSK Annual Report 2025, 5 Mar 2026, p. 34

GSK announced that it had acquired Elsie Biotechnologies, a San Diego-based private biotechnology company dedicated to unlocking the full potential of oligonucleotide therapeutics, for a total consideration of up to US$51 million

GSK Annual Report 2025, 5 Mar 2026, p. 245

Deliver digital, data and tech milestones ... Excellent progress across the R&D data/AI technology goals driving improvements in cycle time, cost and attrition

GSK Annual Report 2025, 5 Mar 2026, p. 153

£45m GSK funding allocated to six new research programmes combining expertise and using cutting edge AI technology to accelerate AMR research

GSK and Fleming Initiative scientists unite to target AMR with advanced AI, 18 Nov 2025

Third, the Board is acutely aware that these priorities can only be fulfilled through ambitious adoption of technology. ... potential for advanced technologies, including AI, to bring medicines and vaccines to patients with more precision, pace and probability of success.

GSK Annual Report 2025, 5 Mar 2026, p. 11

we continue to invest significantly in the transformational capability afforded by AI/ML

GSK Annual Report 2025, 5 Mar 2026, p. 10

External innovation and BD enhance pipeline and R&D effectiveness ... AI foundation models ... Chai2 AI system ... Enhancing Research ... Platforms, technology & multi-therapy area

Q2 2026 Results & Accelerate Growth slides, 28 Jul 2026, p. 31

Data and technology enable faster decision making and a higher confidence portfolio (PTRS)

Q2 2026 Results & Accelerate Growth slides, 28 Jul 2026, p. 28

What it shows running: Delivery 4, live

Our digital chemistry platform uses AI/machine learning (ML) and automation to accelerate design-build-test cycles in small-molecule discovery.

GSK Annual Report 2025, 5 Mar 2026, p. 34

Our AI-powered, end-to-end oligonucleotide platform, 'Oligopolis', which incorporates the Elsie platform we acquired in 2024, is redefining research in chemistry and biology. The platform automates cycles of design, synthesis and testing

GSK Annual Report 2025, 5 Mar 2026, p. 34

GSK uses these AI methods to compare expression data from healthy lung tissue with samples from COPD patients

Mapping disease at the cellular level: A single-cell revolution in drug discovery (Behind the Science), 12 Dec 2025

In COPD, our data-driven disease models combine human genetics, genomics, cell biology and clinical studies ... helped us validate and prioritise IL-33 and ... (TSLP) as promising targets ... potential to reduce research timelines and costs by up to tenfold

GSK Annual Report 2025, 5 Mar 2026, p. 35

chemists, microbiologists and AI experts at Imperial ... will partner with GSK

GSK and Fleming Initiative scientists unite to target AMR with advanced AI, 18 Nov 2025

the integration of GenAI and agentic AI into our discovery process significantly enhances our ability to identify genetically validated targets and optimise molecular pathways.

GSK Annual Report 2025, 5 Mar 2026, p. 34

AI-powered phenotype analysis using UK Biobank data has reduced research timelines by over 50% in Metabolic Dysfunction-Associated Steatohepatitis (MASH).

GSK Annual Report 2025, 5 Mar 2026, p. 35

This helped us validate and prioritise IL-33 and thymic stromal lymphopoietin (TSLP) as promising targets for new treatments and has the potential to reduce research timelines and costs by up to tenfold.

GSK Annual Report 2025, 5 Mar 2026, p. 35

Commitments made public in the last 12 months: 3

  • Relation Therapeutics target-discovery collaborations: Relation announces expanded collaboration to generate perturbation datasets for foundation-model training and target discovery. Expanded, announced, 30 Jul 2026. Published by: partner only.
  • Noetik OCTO-VC foundation model licence: Five-year non-exclusive licence to Noetik's virtual-cell foundation models for NSCLC and colorectal cancer. New, announced, 8 Jan 2026. Published by: partner release, company quoted.
  • GSK-Teichmann Laboratory single-cell collaboration: New single-cell and spatial genomics collaboration for lung, liver and kidney drug discovery, with AI foundation models for analysis. New, operational, 12 Dec 2025. Published by: company.

Commitments made public in the year before: 2

Search coverage for this theme: partial. Commitments count once per initiative, however many announcements they get.

R&D roles open on 6 October 2026: 2

These are postings listed on one day, not hires, headcount or a trend. Roles that serve both themes appear under each.

Research labs and data

What the company says: Priority 5

In 2025, we accelerated and expanded the deployment of advanced data and platform technologies end-to-end in R&D.

GSK Annual Report 2025, 5 Mar 2026, p. 34

by integrating advanced computational protein modelling with an end-to-end automated lab-in-the-loop platform. This closes the design-build-test cycle so we can reliably deliver therapeutic large molecules, faster.

GSK Annual Report 2025, 5 Mar 2026, p. 34

our AI/ML-powered lab-in-the-loop automated systems, which scale experimentation and reduce resource duplication, are redefining how we optimise therapies in HIV and immunology.

GSK Annual Report 2025, 5 Mar 2026, p. 35

We use advanced data assets, digital capabilities and generative AI (GenAI) to gain deeper insights into patients, human biology and disease mechanisms. Our teams use our diverse, deep and proprietary data sources

GSK Annual Report 2025, 5 Mar 2026, p. 34

The GSK site will feature state-of-the-art, tech-enabled labs and infrastructure to support research

GSK to establish new flagship R&D centre on Cambridge Biomedical Campus, UK, 28 Jul 2026

Overall, the company plans to invest £400 million over 3 years in support of these changes.

GSK to establish new flagship R&D centre on Cambridge Biomedical Campus, UK, 28 Jul 2026

State-of-the-art, tech-enabled labs within biotech and AI ecosystem

Q2 2026 Results and Accelerate Growth slides, 28 Jul 2026, p. 33

Our AI-powered, end-to-end oligonucleotide platform, 'Oligopolis', which incorporates the Elsie platform we acquired in 2024, is redefining research in chemistry and biology. The platform automates cycles of design, synthesis and testing

GSK Annual Report 2025, 5 Mar 2026, p. 34

GSK announced that it had acquired Elsie Biotechnologies, a San Diego-based private biotechnology company dedicated to unlocking the full potential of oligonucleotide therapeutics, for a total consideration of up to US$51 million

GSK Annual Report 2025, 5 Mar 2026, p. 245

What it shows running: Delivery 4, live

by integrating advanced computational protein modelling with an end-to-end automated lab-in-the-loop platform. This closes the design-build-test cycle so we can reliably deliver therapeutic large molecules, faster.

GSK Annual Report 2025, 5 Mar 2026, p. 34

our AI/ML-powered lab-in-the-loop automated systems, which scale experimentation and reduce resource duplication, are redefining how we optimise therapies in HIV and immunology.

GSK Annual Report 2025, 5 Mar 2026, p. 35

In 2025, we accelerated and expanded the deployment of advanced data and platform technologies end-to-end in R&D.

GSK Annual Report 2025, 5 Mar 2026, p. 34

Commitments made public in the last 12 months: 0

None identified in the reviewed sources.

Commitments made public in the year before: 0

None identified in the reviewed sources.

Search coverage for this theme: partial. Commitments count once per initiative, however many announcements they get.

R&D roles open on 6 October 2026: 3

These are postings listed on one day, not hires, headcount or a trend. Roles that serve both themes appear under each.

Technology named in these postings

Named as in use: MyLabData.

A product named in a job advert shows what a team wants people to know. It is not proof of a purchase or an installed system.

Two questions to investigate (Ortent's interpretation)

  1. Who decides on new lab robotics and lab data systems across R&D Digital and Tech, the lab teams in Cambridge, Massachusetts and the R&D Technologies group, and does that change with the move from Stevenage to Cambridge, UK by 2029?
  2. Who decides whether GSK licenses an external AI discovery model, as with Noetik and Relation, or builds its own in the AI for Science team, and does that spend go through the Data, AI and Infrastructure procurement category, business development or another route?

Coverage limits

Business Wire, GlobeNewswire, Fierce Biotech, Pharmaceutical Technology and the UK Biobank site blocked access, so partner releases were read through copies on 1stOncology and BioSpace. The Q2 2026 results transcript was not found, so the search for the last 12 months is partial and the two years cannot be compared like for like. Annual report publication dates could not be confirmed, and SEC filings and patents were not searched. The scores rest on the documents that could be read, and missing ones could hold further evidence.

// GET IN TOUCH

Clarity when it counts.

For a board, advisory or fractional engagement, or a working call on the next stage, send a note. Thirty minutes is usually enough to test fit.

Request a 30-minute intro call